A record to read carefully

Semaglutide: evidence profile

Approved product · Randomized evidence

Status recorded · Page published

Read the product, route and approval scope together. A category label does not replace those details. Use the exercise to prepare questions, not to choose a treatment.

Evidence record

Product and route
This entry covers subcutaneous Wegovy injection.
Approval scope
Wegovy injection: weight management in eligible adults.
Mechanism
Activates the GLP-1 receptor.
Evidence
Randomized trials.
Limits
Check other products separately.
Safety context
Severe or persistent gastrointestinal symptoms: contact a clinician.

Try this while reading

A screenshot can lose the small heading that explains a result. When saving a semaglutide discussion, add a sentence that spells out what the number measures and the unit attached to it. If a percentage appears, look for the amount or group used to calculate it. Try explaining the result aloud without saying just the number. Could a listener mistake a change in an amount for a change in a percentage? Return to the heading or methods until you can make that distinction. Keep the explanation with your saved image so a future comparison starts with quantities that actually match.

Questions to keep

  1. What heading must stay with this screenshot for the number to make sense?
  2. What amount or group is the percentage calculated from?
  3. Am I comparing the same kind of quantity in both saved results?

Sources to open

Checked dates belong to the linked records, rather than to this page's publication.

  1. WEGOVY — NLM; checked
  2. Wegovy approval — FDA; checked